文献速递血栓与止血

Efanesoctocog alfa治疗A型血友病:1期重复给药研究结果

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
PubMed 文献 · Blood Adv · 2022-01-01

这项1期研究评估了Efanesoctocog alfa在重型A型血友病既往治疗成人中每周1次重复给药的安全性、耐受性和药代动力学。队列1(50 IU/kg,n=10)和队列2(65 IU/kg,n=14)均完成4次给药,未检出FVIII抑制物,未报告出血事件。末次给药后FVIII活性半衰期队列1为41.3小时、队列2为37.3小时,给药后3至4天FVIII活性维持在正常至接近正常范围。

要点

  • 两个队列均完成每周1次共4次给药,未检出FVIII抑制物,治疗期间未报告出血事件。
  • 末次给药后FVIII活性半衰期队列1为41.3小时,队列2为37.3小时。
  • 给药后3至4天FVIII活性维持在正常至接近正常范围,4次给药后蓄积极少。

核心结论

  • 每周1次Efanesoctocog alfa耐受良好,未发现安全性问题,治疗期间未报告出血。
  • 每周1次给药后3至4天内提供高而持续的FVIII活性,处于正常至接近正常范围,可能改善A型血友病患者的出血保护。

研究设计与样本

  • 1期研究,纳入既往接受过治疗(暴露日≥150天)的重型A型血友病成人。
  • 参与者接受4次每周1次Efanesoctocog alfa:队列1为50 IU/kg(n=10),队列2为65 IU/kg(n=14)。
  • 所有入组参与者(队列1 n=10;队列2 n=14)均完成研究。
  • 试验注册号为EU Clinical Trials Register研究2018-001535-51。

主要发现

  • 未检出针对FVIII的抑制物。
  • 末次给药后FVIII活性半衰期几何均值(范围):队列1为41.3(34.2-50.1)小时,队列2为37.3(28.9-43.8)小时。
  • 活性-时间曲线下面积几何均值(范围):队列1为8290(5810-10300)小时×IU/dL,队列2为11200(7040-15800)小时×IU/dL。
  • 稳态最大浓度几何均值(范围):队列1为131(96-191)IU/dL,队列2为171(118-211)IU/dL。
  • 4次给药后蓄积极少;给药后第3天平均FVIII活性队列1为46%、队列2为69%,给药后第7天队列1为10%、队列2为12%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Efanesoctocog alfa (rFVIIIFc-VWF-XTEN; BIVV001) is a new class of factor VIII (FVIII) replacement that breaks the von Willebrand factor-imposed FVIII half-life ceiling. In a phase 1/2a study, single-dose efanesoctocog alfa was well tolerated, and no safety concerns were identified. We evaluated the safety, tolerability, and pharmacokinetics of repeat-dose efanesoctocog alfa in a phase 1 study in previously treated adults (≥150 exposure days) with severe hemophilia A. Participants received 4 once weekly doses of efanesoctocog alfa (cohort 1, 50 IU/kg; cohort 2, 65 IU/kg). All enrolled participants (cohort 1, n = 10; cohort 2, n = 14) completed the study. Inhibitor development to FVIII was not detected. After the last dose of efanesoctocog alfa, geometric mean (range) FVIII activity half-life, area under the activity-time curve, and steady-state maximum concentration for cohort 1 and cohort 2 were 41.3 (34.2-50.1) and 37.3 (28.9-43.8) hours, 8290 (5810-10 300) and 11 200 (7040-15 800) hours × IU/dL, and 131 (96-191) and 171 (118-211) IU/dL, respectively. There was minimal accumulation after 4 doses. Mean FVIII activity for cohort 1 and cohort 2, respectively, was 46% and 69% on day 3 postdose and 10% and 12% on day 7 postdose. Overall, 4 once-weekly doses of efanesoctocog alfa were well tolerated, no safety concerns were identified, and no bleeds were reported during the treatment period. Once-weekly efanesoctocog alfa provided high sustained FVIII activity within the normal to near-normal range for 3 to 4 days postdose and may improve protection against bleeds in patients with hemophilia A. The trial is study 2018-001535-51 in the EU Clinical Trials Register.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022. PMID: 34794179. doi:10.1182/bloodadvances.2021006119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。